Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
Journal for ImmunoTherapy of Cancer · 2023-10 · 11 (10) · e007047
DOI: 10.1136/jitc-2023-007047 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 30.10.2023. Verfasst von Caicun Zhou und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Affiliated Shanghai Pulmonary Ho…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Background
Tumor samples from the phase III IMpower010 study were used to compare two programmed death-ligand 1 (PD-L1) immunohistochemistry assays (VENTANA SP263 and Dako 22C3) for identification of PD-L1 patient subgroups (negative, positive, low, and high expression) and their predictive value for adjuvant atezolizumab compared with best supportive care (BSC) in resectable early-stage non-small cell lung cancer (NSCLC).
Methods
PD-L1 expression was assessed by the SP263 assay, which measured the percentage of tumor cells with any membranous PD-L1 staining, and the 22C3 assay, which scored the percentage of viable tumor cells showing partial or complete membranous PD-L1 staining.
Results
When examining the concordance at the PD-L1-positive threshold (SP263: tumor cell (TC)≥1%; 22C3: tumor proportion score (TPS)≥1%), the results were concordant between assays for 83% of the samples. Similarly, at the PD-L1–high cut-off (SP263: TC≥50%; 22C3: TPS≥50%), the results were concordant between assays for 92% of samples. The disease-free survival benefit of atezolizumab over BSC was comparable between assays for PD-L1-positive (TC≥1% by SP263: HR, 0.58 (95% CI: 0.40 to 0.85) vs TPS≥1% by 22C3: HR, 0.65 (95% CI: 0.45 to 0.95)) and PD-L1-high (TC≥50% by SP263: HR, 0.27 (95% CI: 0.14 to 0.53) vs TPS≥50% by 22C3: HR, 0.31 (95% CI: 0.16 to 0.60)) subgroups.
Conclusions
The SP263 and 22C3 assays showed high concordance and a comparable clinical predictive value of atezolizumab at validated PD-L1 thresholds, suggesting that both assays can identify patients with early-stage NSCLC most likely to experience benefit from adjuvant atezolizumab. Trial registration number NCT02486718 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China caicunzhou_dr@163.com.
- Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA.
- F. Hoffman-La Roche Ltd, Mississauga, Ontario, Canada.
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
- Stanford University School of Medicine, Stanford Cancer Institute, Stanford, California, USA.
- Department of Cardiothoracic Surgery, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, New York, USA.
ORCID-Profile: Caicun Zhou
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Zhou, C., Srivastava, M. K., Xu, H., Felip, E., Wakelee, H., Altorki, N., Reck, M., Liersch, R., Kryzhanivska, A., Oizumi, S., Tanaka, H., Hamm, J., McCune, S. L., Bennett, E., Gitlitz, B., McNally, V., Ballinger, M., McCleland, M., Zou, W., …, & Novello, S. (2023). Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. Journal for ImmunoTherapy of Cancer, 11(10), e007047. https://doi.org/10.1136/jitc-2023-007047
Vancouver
Zhou C, Srivastava MK, Xu H, Felip E, Wakelee H, Altorki N, et al. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. Journal for ImmunoTherapy of Cancer. 2023;11(10):e007047. doi:10.1136/jitc-2023-007047
BibTeX
@article{Zhou2023,
author = {Zhou, Caicun and Srivastava, Minu K and Xu, Hao and Felip, Enriqueta and Wakelee, Heather and Altorki, Nasser and Reck, Martin and Liersch, Rüdiger and Kryzhanivska, Anna and Oizumi, Satoshi and Tanaka, Hiroshi and Hamm, John and McCune, Steven L and Bennett, Elizabeth and Gitlitz, Barbara and McNally, Virginia and Ballinger, Marcus and McCleland, Mark and Zou, Wei and Das Thakur, Meghna and Novello, Silvia},
title = {Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {10},
pages = {e007047},
doi = {10.1136/jitc-2023-007047}
}
EUVIMED